TY  - GEN
AU  - Bendell,Johanna C
AU  - Lenz,Heinz-Josef
AU  - Ryan,Theresa
AU  - El-Rayes,Bassel F
AU  - Marshall,John L
AU  - Modiano,Manuel R
AU  - Hart,Lowell L
AU  - Kingsley,Clint D
AU  - George,Thomas J
AU  - Nakashima,Daisuke
AU  - Berlin,Jordan D
TI  - Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer
SN  - 1573-0646
PY  - 2015///0302
KW  - Adolescent
KW  - Adult
KW  - Antibodies, Monoclonal
KW  - adverse effects
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Agents, Phytogenic
KW  - therapeutic use
KW  - Camptothecin
KW  - analogs & derivatives
KW  - Colorectal Neoplasms
KW  - drug therapy
KW  - Disease Progression
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Irinotecan
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Membrane Glycoproteins
KW  - antagonists & inhibitors
KW  - Middle Aged
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1007/s10637-014-0088-3
ER  -